anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Porcine rotavirus (RV) is a major viral agent associated with severe diarrhea in newborn piglets. RVA, RVB, RVC, and RVH are RV species that have already been identified in pigs. RVA is considered the most prevalent and relevant virus in pig production worldwide. This study aimed to evaluate the frequency of RV infection associated with diarrhea in suckling piglets from regular RVA-vaccinated Brazilian pig herds between 2015 and 2021. Therefore, 511 diarrheic fecal samples were collected from suckling piglets aged up to 3 weeks from 112 pig farms located in three main Brazilian pork production regions. All piglets were born to RVA-vaccinated sows. The nucleic acids of RVA, RVC, and RVH were investigated by RT-PCR assays and RVB by semi-nested RT-PCR assay. Of the diarrheic fecal samples analyzed, 221/511 (43.3%) were positive for at least one of the RV species. Regarding the distribution of RV species among the positive fecal samples that presented with only one RV species, 99 (44.8%), 63 (28.5%), and 45 (20.4%) were identified as RVB, RVC, and RVA, respectively. RVH was not identified in diarrheic piglets with a single infection. More than one RV species was identified in 14/221 (6.3%) of the diarrheic fecal samples evaluated. Co-detection of RVB + RVH (11/221; 5.0%), RVA + RVB (1/221; 0.4%), RVA + RVC (1/221; 0.4%), and RVB + RVC (1/221; 0.4%) was identified in fecal samples. The results demonstrated a significant increase in the RVC and, mainly, RVB detection rates in single infections. This study allowed us to characterize the importance of other RV species, in addition to RVA, in the etiology of neonatal diarrhea in piglets from pig herds with a regular vaccination program for RVA diarrhea control and prophylaxis.
1. Obtain a Baker-Flex Aluminum Oxide coated, plastic TLC plate, #1 B-F, pre-cut to 2.5 cm x 7.5 cm. 
  2. Dry the plate or plates at 100°C for 1 hour and store in a desiccator. Remove pre-dried plate from the desiccator just prior to use. 
  3. Apply 1 drop of ethanol* using a 1 mL syringe with a 22-26 gauge needle, 1.5 cm from the bottom of the plate. THE SPOT SHOULD NOT BE ALLOWED TO DRY. 
  4. Add 2 drops of Technetium Tc99m Sestamibi solution, side by side on top of the ethanol* spot. Return the plate to a desiccator and allow the sample spot to dry (typically 15 minutes). 
  5. The TLC tank is prepared by pouring ethanol* to a depth of 3-4 mm. Cover the tank and let it equilibrate for ~10 minutes. 
  6. Develop the plate in the covered TLC tank in ethanol* for a distance of 5 cm from the point of application. 
  7. Cut the TLC plate 4 cm from the bottom and measure the Tc99m activity in each piece by appropriate radiation detector. 
  8. Calculate the % Tc99m Sestamibi as:



*The ethanol used in this procedure should be 95% or greater. Absolute ethanol (99%) should remain at ≥95% ethanol content for one week after opening if stored tightly capped, in a cool dry place.
Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
The E-STIM Trial is designed to collect data on the efficacy of the Empi Select Transcutaneous Electrical Nerve Stimulation (TENS) device for the treatment of chronic low back pain. This clinical trial is a non-significant risk, randomized, double-blinded, placebo-controlled 12-week trial involving the commercially available Empi Select TENS device for treating subjects with chronic (\>90 days) low back pain. Multiple centers located in the United States will enroll approximately 300 subjects in this study. Eligible subjects will be randomized 1:1 to either the treatment group or the placebo group. The subjects and investigational staff are blinded to the treatment assignment. Subjects will return to the investigational center for follow-up assessments at 1, 4, 8, and 12 weeks.
Prematurity is the leading cause for mortality and morbidity in newborns with very low birth weight (VLBW) infants (\< 1500g birth weight) at highest risk. Ten to thirty percent of VLBW infants are also born too small for their gestational age defined by a birth weight below the 10th percentile. In daily neonatal intensive care, consequential long term-follow up and most studies all growth restricted premature infants are treated the same, importantly this includes the nutritional management after birth. However, different groups of patients with different causal pathologies are subsumed under the definition growth restriction or born too small. One group of growth restricted patients refers to the infants born constitutionally small or small for gestational age (SGA). The other group refers to infants with an intrauterine growth restriction (IUGR) caused by a complex antenatal pathology. Consequently, the nutritional management after birth is very important to minimize the potential risk for developing obesity, diabetes and cardiovascular diseases later in life and to achieve optimal growth. So far we do not consider the different underlying pathomechanisms of growth restriction in our nutritional concepts for preterm infants and therefore cause long-term consequences. The European society of pediatric gastroenterology, hematology and nutrition (ESPGHAN) recommends to feed enhanced nutrients up to 52nd week of gestation in all growth restricted preterm infants- regardless if they are SGA or IUGR premature. Actually, reliable data guaranteeing that the recommended "enhanced nutrients strategy" providing extra nutrients up to 52 weeks for SGA and IUGR infants is safe and effective for both groups in terms of long-term growth and metabolic programming are lacking.

A total of 348 preterm infants born and discharged below the 10th percentile at term will be included in the study and stratified according to SGA or IUGR by a combination of antenatal ultrasound parameters and growth parameters (including 10% screening failures and 20% drop out. Furthermore IUGR and SGA growth restricted preterm infants will be stratified according to breastfeeding or formula feeding and randomized in one of the following groups: Standard nutrients group (breastfeeding or starter formula) or Enhanced nutrients group (fortified breast milk or post-discharge formula. Body composition measurements will be performed by air displacement plethysmography - a non-invasive method. Anthropometric measurements will be performed by measuring weight, height and head circumference. Furthermore, parameters of metabolic programming, metabolomics, the stool microbiome and neurodevelopmental outcome will be determined. Additionally, the stool microbiome will be characterized from infant stool samples and compared between the two groups. After an interventional period of three months infants will be followed up until 2 years of age.
Participants in the active arm will take 15 capsules of coffee, each of which will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend (equivalent daily dose: three cups of coffee). Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
BACKGROUND: Although immune checkpoint inhibitors (ICIs) have revolutionized the landscape of cancer treatment, only a minority of colorectal cancer (CRC) patients respond to them. Enhancing tumor immunogenicity by increasing major histocompatibility complex I (MHC-I) surface expression is a promising strategy to boost the antitumor efficacy of ICIs.
METHODS: Dual luciferase reporter assays were performed to find drug candidates that can increase MHC-I expression. The effect of nilotinib on MHC-I expression was verified by dual luciferase reporter assays, qRT-PCR, flow cytometry and western blotting. The biological functions of nilotinib were evaluated through a series of in vitro and in vivo experiments. Using RNA-seq analysis, immunofluorescence assays, western blotting, flow cytometry, rescue experiments and microarray chip assays, the underlying molecular mechanisms were investigated.
RESULTS: Nilotinib induces MHC-I expression in CRC cells, enhances CD8+ T-cell cytotoxicity and subsequently enhances the antitumor effects of anti-PDL1 in both microsatellite instability and microsatellite stable models. Mechanistically, nilotinib promotes MHC-I mRNA expression via the cGAS-STING-NF-κB pathway and reduces MHC-I degradation by suppressing PCSK9 expression in CRC cells. PCSK9 may serve as a potential therapeutic target for CRC, with nilotinib potentially targeting PCSK9 to exert anti-CRC effects.
CONCLUSION: This study reveals a previously unknown role of nilotinib in antitumor immunity by inducing MHC-I expression in CRC cells. Our findings suggest that combining nilotinib with anti-PDL1 therapy may be an effective strategy for the treatment of CRC.
After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery. Approximately 80% of these patients will be assigned to the single study arm (no axillary SLNB) due to breast pCR (ypT0/ypTis) at the final pathology of lumpectomy.
An agent for curing states of illness in the digestive apparatus comprising fish fermented by a fermentation process in brine. According to a first method for the production of the agent the fermented fish is encased in capsules that are essentially impermeable to the scent agents that are emitted by the fermented fish. According to a second method for the production of the agent fermented fish in a finely divided form is formed into units, for instance tablets or cookies, and is brought into an essentially solid form. The invention also comprises use of a preparation comprising fermented fish for curing states of illness in the digestive apparatus. Likewise, the invention comprises a method for curing states of illness in the digestive apparatus, wherein a preparation comprising fermented fish is administered to a patient/an animal. Furthermore, the invention comprises an animal feeding stuff comprising fermented fish and methods for the production of such an animal feeding stuff.
A clear gel cosmetic stick is disclosed which includes a liquid vehicle, an antiperspirant salt dissolved in the liquid vehicle, and a dibenzylidene alditol, and is further characterized in that said stick includes a hydroxyalkyl cellulose or a chelating agent or both a hydroxyalkyl cellulose and a chelating agent. The cosmetic stick comprises in percent by weight about 70 % to about 95 %, preferably 75 % to 92 %, of a liquid vehicle, about 1 % to about 22 %, preferably 3 % to 15 %, of an antiperspirant salt dissolved in said vehicle, about 0.5 % to about 3 %, preferably 0.5 % to 1.5 %, of a dibenzylidene alditol, about 0.1 % to about 0.5 %, preferably 0.2 % to 0.4 %, of a hydroxyalkyl cellulose, and about 0.05 % to about 3 %, preferably 0.1 %  to 2 %, of a chelating agent. Preferably, the liquid vehicle comprises a polyhydric alcohol having from 3 to 6 carbon atoms and from 2 to 6 hydroxyl groups and is substantially free of monohydric alcohol and strong alkali such as sodium hydroxide and potassium hydroxide. Preferably, the cosmetic stick will have a pH greater than 4.4, more preferably greater than 4.7, a turbidity of less than about 120 NTU, more preferably less than 100 NTU, and a hardness of about 60 to 150. By lowering the dibenzylidene alditol level to 1.5 % or lower, the clarity and odor characteristics of the stick are greatly improved.  The hardness of the stick is maintained by the addition of the hydroxyalkyl cellulose. The color of the stick is improved by the addition of the chelating agent.
The purpose of this study is to expand our understanding of the metabolic effects of darunavir/ritonavir (DRV/r) in HIV-infected patients. This is a phase 4, multicenter, open-label, randomized (study drug assigned by chance), comparative study designed to compare changes in lipid, glucose, and insulin parameters in HIV-infected, anti-retroviral (ARV) naive patients treated with DRV/r 800/100 mg once daily (QD) versus atazanavir/ritonavir (ATV/r) 300/100 mg QD in combination with a common background of emtricitabine (FTC)/ tenofovir (TDF) 200/300 mg QD. In addition, changes in inflammatory markers will be measured. A substudy of the parent study TMC114HIV4023 will evaluate insulin sensitivity and endothelial function in a subset of patients. The study will be conducted at approximately 16 study sites in the United States. Approximately 60 HIV-1 infected, treatment-naive adult patients will be enrolled in the study. Screening will take place during a 4-week period. At the baseline visit, eligible patients will be randomized in a 1:1 ratio to receive DRV/r 800/100 mg QD or ATV/r 300/100 mg QD administered in combination with a fixed-dose background regimen consisting of emtricitabine (FTC)/tenofovir (TDF) 200/300 mg once daily. The treatment period is 48 weeks. Study assessments will be performed at clinic visits at the end of weeks 4, 8, 12, 24, 36, and 48. The primary endpoint will be assessed at week 12. All patients will return for follow up visits 1 week and 4 weeks after the completion of study treatment. During the treatment period, the patient will be seen at regular visits during which the investigator will assess the patient's medical condition, any Adverse Events and study drug compliance. Laboratory evaluations for efficacy and safety will be done at regular visits as well as blood pressure monitoring. Up to twenty patients (evenly randomized to receive DRV/r or ATV/r) who meet additional entry criteria will be enrolled in the substudy. The study hypothesis is the change in triglycerides and other lipids from baseline to week 12 will be similar in the DRV/r arm versus the ATV/r arm. The substudy hypothesis is that DRV/r will not adversely affect insulin sensitivity or endothelial function during 12 weeks of therapy, and the change from baseline in insulin sensitivity and endothelial function will be similar in the DRV/r arm versus the ATV/r arm. During the treatment period, the patient will be seen at regular visits during which the investigator will assess the patient's medical condition, any Adverse Events and study drug compliance. Laboratory evaluations for efficacy and safety will be done at regular visits as well as blood pressure monitoring. Patients will be randomized in a 1:1 ratio to receive darunavir/ritonavir 800/100 mg once daily (QD) plus emtricitabine (FTC)/tenofovir (TDF) 200/300 mg QD or atazanavir/ritonavir 300/100 mg QD plus emtricitabine (FTC)/tenofovir (TDF) for 48 weeks.
The invention relates to a method for extracting, separating and purifying nano particles (nano particles/carbon points/nano components) from lotus rhizome node carbon, which comprises the following steps: the lotus node carbon is extracted or extracted by a solvent and dialyzed by a dialysis bag or ultrafiltered to obtain the lotus node carbon nano particles. The particle size of the nano particle is less than 10nm, and the nano particle mainly comprises C, H, O, N and other elements; has low toxicity to cells. In vivo experiments show that the lotus rhizome node carbon nano particles can obviously reduce gastric mucosa injury and obviously improve the levels of superoxide dismutase (SOD), Catalase (CAT), Glutathione (GSH) and glutathione peroxidase (GSH-px). In addition, the lotus node carbon nano-particles can also obviously inhibit the levels of tumor necrosis factor- (TNF-a) and proinflammatory interleukin-6 (IL-6) in stomach tissues. The histological research shows that the lotus node carbon nano-particles have a protective effect on tissue change in the ethanol-induced ulcer reaction. The invention discloses that the lotus rhizome node carbon nano particles have stronger stomach protection effect.
Renal fibrosis is a common pathological feature of chronic kidney disease (CKD) with the proliferation and activation of myofibroblasts being definite effectors and drivers. Here, increased expression of Meis1 (myeloid ecotropic viral integration site 1) is observed, predominantly in the nucleus of the kidney of CKD patients and mice, and negatively correlates with serum creatinine. Fibroblast-specific knock-in of Meis1 inhibits myofibroblast activation and attenuates renal fibrosis and kidney dysfunction in CKD models. Overexpression of Meis1 in NRK-49F cells suppresses the pro-fibrotic response induced by transforming growth factor-β1 but accelerates by its knockdown. Mechanistically, Meis1 targets protein tyrosine phosphatase receptor J (Ptprj) to block renal fibrosis by inhibiting the proliferation and activation of fibroblasts. Finally, a new activator of Ptprj is identified through computer-aided virtual screening, which has the effect of alleviating renal fibrosis. Collectively, these results illustrate that the Meis1/Ptprj axis has therapeutic potential for clinically treating CKD.
A treatment system according to the invention comprises a chamber, treatment fluid, treatment additives, control over treatment variables and monitoring capabilities. The chamber encloses a predetermined surface area about the wound. The chamber provides protection from the wound from the surrounding non-sterile environment, control of treatment variables, containment for continuous fluid treatment, an effective delivery system, an effective interface between the wound and the environment, direct monitoring of wound physiology and wound diagnosis. The treatment system provides monitoring of the wound which is essential to enhancing the healing process. Monitoring constitutes extraction and analysis of the system fluid and clinical wound diagnosis. The system provides visual monitoring of the wound itself as well as the fluid within the system. The monitoring features of the system, in addition to the precise control over treatment variables, facilitates research.
Process comprises cutting animal lymphatic glands into small pieces after connecting tissues and fat has been removed. A mixture of the pieces and water in the ratio 1:2 to 1:4 is distilled, then stirred and heated to 90 degrees C and the extract removed over 15 mins. The extract is vacuum filtered and the filtrate obtained cooled to 50 degrees C after which it is treated in an autoclave at is approx. 120 for 90 mins. Before placing it in the autoclave for a 2nd. time the extract is cooled to 5 degrees C and filtered. Prod. is used for immunologically treating malignant tumours.
The invention discloses the method for the continuous micron and/or nano particle for preparing one pack system particle or multi component particle (such as graininess amorphous solid dispersion or graininess eutectic).The continuation method comprises the following steps：1. prepare the first solution comprising at least one component and at least one solvent and the second solution of at least one anti-solvent comprising at least one component contained in first solution；2. mix first solution and second solution by way of Micro Fluid, with by precipitating or co-precipitation prepares suspension；3. the suspension is fed to filtration system to obtain concentration logistics；4. the concentrate is flowed into material to spray dryer；5. the concentration logistics is atomized using at least one atomizer；6. the concentration logistics of the drying atomization is to obtain particle；And 7. collect the particle.The invention also discloses one pack system particle or multi component particle, graininess amorphous solid dispersion, graininess eutectic and pharmaceutical composition.
This study aims to compare the effect of unilateral and bilateral rTMS on the reduction of rumination and anhedonia and their associated neural networks. In a randomized double-blind trial, 65 patients with depressive disorder in Atieh Clinical Neuroscience Center are assigned to three groups. The first group receives bilateral rTMS for 20 sessions on right and left DLPFC; the second group receives unilateral rTMS for 20 sessions on LDLPFC; third group receives sham rTMS for 10 sessions. In this group, the stimulation parameters are similar to that in the actual rTMS group, except that the coil angel is 90° and perpendicular to the head. Rumination and anhedonia symptoms will be measured by the Ruminative Responses Scale (RRS) and Snaith-Hamilton Pleasure Scale (SHAPS) in the baseline and after the 20th session. In order to investigate the neural networks associated with rumination and anhedonia, EEG of patients will be recorded at the first session and at the end of the treatment.
MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will receive personalized feedback on their MJ use and will be provided a smart phone app on which they report their MJ use episodes, which also is designed to promote the use of exercise/physical activity as an alternative to MJ use. Level of Physical activity will be measured using accelerometers.
A container (1), designed to be retained in contact with a patient's skin to administer a homeopathic treatment by the transmission of negatively charged electrons, is made from a supple, transparent but colored plastic material. It comprises lower (2) and upper (3) compartments linked through a narrow neck (4) that allows a solution to pass from one to the other. The container (1), designed to be retained in contact with a patient's skin to administer a homeopathic treatment by the transmission of negatively charged electrons, is made from a supple, transparent but colored plastic material. It comprises lower (2) and upper (3) compartments linked through a narrow neck (4) that allows a solution to pass from one to the other. The neck has a cross-section of at least one square cm, while the neck (7) of the upper compartment is closed by a stopper (6) which is sealed after filling. The container can be shaped according to the part of the body to be treated, e.g. in the shape of a shoe insole to treat the foot, and solid portion of the container or adjacent membrane (9) has holes (8) for a fastening cord.
A filling for a tooth cavity is prepared by pressing physiologically inert polymeric synthetic resins in the form of granules or particles, sufficiently small in size to be coalesced by pressure, to form a solid coherent mass and further consolidating the mass into a coherent homogeneous body.  The resin particles may include fibrous portions.  Specified resins are polymers of ethylene and substituted ethylene, particularly polyethylene, polystyrene, polyisobutylene, polyvinyl chloride, polytetrafluoroethylene, polychlorotrifluoroethylene, polyacrylonitrile, polymethyl methacrylate, polymethyl acrylate; and polyamides, polyesters, polycarbonates, cellulose derivatives, phenoplasts and melamine resins.  The resins may be used in admixture, or mixed with fillers and pigments.ALSO:In a method of producing a filling for a tooth cavity physiologically inert polymeric synthetic resin in the form of granules or particles sufficiently small to be coalesced by pressure is formed by pressure into a solid coherent mass and is converted by further consolidation into a coherent homogeneous body.  Pressure may be applied by conventional dental instruments, mechanically driven vibrators or ultrasonic apparatus.  The resin particles are coalesced by light pressure to form a pellet which is introduced into the cavity and further consolidated.  The resin may be mixed with other resins, fillers such as calcium hydroxide and medicaments, and the method may be used in the preparation of linings, and temporary and permanent fillings.  Specified resins are polyethylene, polystyrene, polyisobutylene, polyvinyl chloride, polytetrafluoroethylene, polychlorotrifluoroethylene, polyacrylonitrile, polymethyl methacrylate, polymethyl acrylate, polyamides, polyesters, polycarbonates, cellulose derivatives, phenoplasts and melamine resins.